Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

BACKGROUND: Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. METHODS: Patients with primary triple negative breast cancer ≥2 cm received doxor...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Cosimo, Serena, La Verde, Nicla, Moretti, Anna, Cazzaniga, Marina Elena, Generali, Daniele, Bianchi, Giulia Valeria, Mariani, Luigi, Torri, Valter, Crippa, Flavio, Paolini, Biagio, Scaperrotta, Gianfranco, De Santis, Maria Carmen, Di Nicola, Massimo, Apolone, Giovanni, Gulino, Alessandro, Tripodo, Claudio, Colombo, Mario Paolo, Folli, Secondo, de Braud, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685628/
https://www.ncbi.nlm.nih.gov/pubmed/31390375
http://dx.doi.org/10.1371/journal.pone.0220644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685628/
https://www.ncbi.nlm.nih.gov/pubmed/31390375
http://dx.doi.org/10.1371/journal.pone.0220644

Ejemplares similares